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Abstract
Gene-expression profiling has had a considerable impact on our understanding of breast cancer
biology, and more recently on clinical care. Two statistical approaches underlie these
advancements. Supervised analyses have led to the development of gene-expression signatures
designed to predict survival and/or treatment response, which has resulted in the development of
new clinical assays. Unsupervised analyses have identified numerous biological signatures
including signatures of cell type of origin, signaling pathways, and of cellular proliferation.
Included within these biological signatures are the molecular subtypes known as the ‘intrinsic’
subtypes of breast cancer. This classification has expanded our appreciation of the heterogeneity
of breast cancer and has provided a way to sub-classify the disease in a manner that might have
clinical utility. In this Review, we discuss the clinical utility of gene-expression-based assays and
their technical potential as clinical tools vis-a-vis the performance of breast cancer biomarkers that
are the current standard of care.
Introduction
Breast cancer is a devastatingly common disease and there is a considerable need to improve
approaches for prevention, diagnosis and treatment.1 One of the biggest barriers to progress
is the extreme clinical and genetic heterogeneity of the disease. Rapid progress in diagnostic
capabilities has occurred over the past decade, however, breast cancer management is caught
between two worlds: the old world of familiar groupings defined by estrogen receptor (ER)
and HER2 status and a new world of seemingly endless and complex ways to classify breast
cancers for treatment individualization. Although enthusiasm for new genomic discovery
tools should be tempered, many studies conducted using conventional gene-expression
profiling should be vaunted as identifying successful biomarkers. Over the past decade, we
have learnt many valuable lessons from gene-expression profiling studies. The clinical
utility of gene-expression-based assays has been demonstrated with increasing confidence,
© 2011 Macmillan Publishers Limited. All rights reserved
Correspondence to: C. M. Perou, cperou@med.unc.edu.
Competing interests
M. J. Ellis and C. M. Perou declare associations with the following company: BioClassifier. See the article online for full details of the
relationship. A. Prat declares no competing interests.
NIH Public Access
Author Manuscript
Nat Rev Clin Oncol. Author manuscript; available in PMC 2013 July 08.
Published in final edited form as:













particularly with respect to tailoring treatment for the current standard of care in
chemotherapy and hormonal treatment.2–4 In this Review, we present the current status of
clinically applicable gene-expression-based assays, and we discuss their reproducibility as
well as the reproducibility of the biomarkers that are standard of care in breast cancer today.
Clinical gene expression-based assays
A plethora of prognostic and some predictive gene-expression signatures have been
identified for breast cancer; however, most of these signatures identify breast cancer
subtypes that have a similar biology, which encompasses ER status, HER2 status, and
proliferation.5 Improvements offered by gene-expression-based assays must, therefore, go
beyond these known variables, or at least encompass them in ways that are more
quantitative, reproducible, and/or objective than the existing immunohistochemistry (IHC)-
based assays. The main characteristics of five gene-expression-based predictors are shown
in Table 1. Although there are considerable similarities between these predictors,6 there are
enough statistically significant differences across them such that each should be considered
to be unique.7
Oncotype DX® recurrence score
Oncotype DX® (Genomic Health, Redwood City, CA) is a 21-gene quantitative reverse
transcription (qRT)-PCR-based assay and is the most widely used clinical gene-expression
assay in the USA. It is based on the levels of gene expression of 16 cancer-related genes and
five genes for expression normalization using RNA from formalin fixed-paraffin embedded
(FFPE) tumor tissues.8,9 The genes in the assay were selected from 250 candidates that were
tested for association with survival in a cohort of 447 tumor samples, including 233 (52%)
ER-positive samples from the tamoxifen-treated and node-negative cases of the National
Surgical Adjuvant Breast and Bowel Project (NSABP) B-20 clinical trial.10 The final 16-
gene list is weighted by biological processes including proliferation, HER2 and ER
signaling. The resulting recurrence score (RS) is 0 to 100, which translates into three risk-
group categories: low (RS <18), intermediate (RS from 18 to <31) and high (RS ≥31).
In a seminal study, Paik and colleagues11 validated Oncotype DX® in a large cohort of ER-
positive, node-negative tamoxifen-treated patients with breast cancer enrolled in the NSABP
B-14 trial; in this study, the rates of distant recurrence at 10 years were 6.8%, 14.3% and
30.5% for the low-risk, intermediate-risk and high-risk groups, respectively. In a subsequent
validation study,12 Oncotype DX® RS was strongly associated with the risk of death from
breast cancer in a similar cohort and also in patients who did not receive adjuvant systemic
therapy. Importantly, the associations of Oncotype DX® with survival have been found to
be independent from standard clinicopathological variables,11,12 thus showing that this assay
adds information beyond ER and HER2 status, stage, and grade.
More recently, Oncotype DX® has been endorsed by ASCO3 and two expert panels: NCCN
Breast Cancer Clinical Practice Guidelines2 and the 2011 St Gallen International Expert
Consensus.4 These panels consider Oncotype DX® to be useful for patients with ER-
positive, node-negative breast cancer as an aid to decision making for administering
adjuvant chemotherapy. Since its commercialization, over 175,000 assays have been ordered
by more than 7,500 physicians worldwide.
MammaPrint®
MammaPrint® is a microarray-based gene-expression profiling assay that was developed by
Agendia (Amsterdam, the Netherlands) based on the Agilent (Agilent technologies, Santa
Clara, CA) microarray-based platform that analyzed data from 78 patients with node-
negative breast cancers.13 The vast majority of these 78 patients had ER-positive tumors and
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did not receive adjuvant systemic therapy. The 70 genes that comprise the MammaPrint®
assay are proliferation genes and genes associated with invasion and angiogenesis. Since
2002, this signature has been validated on numerous cohorts of node-negative patients,14–16
and has been shown to provide independent prognostic information beyond standard clinico-
pathological variables such as age, histological grade and pathological stage.14
MammaPrint® is also the first FDA-approved gene-expression-based assay to be used as a
prognostic test for women with node-negative breast cancers. Unlike the Oncotype DX®
assay, this test is based on microarrays results and hence requires high-quality RNA from
freshly collected tissues.
MapQuant Dx™ genomic grade
MapQuant Dx™ (Ipsogen, Marseille, France) is a predictor test that was derived by
identifying 97 differentially expressed genes from grade 1 and 3 breast tumors using a
training set of 64 ER-positive tumors;17 most of the genes in this signature are involved in
cell-cycle regulation and proliferation. In validation data sets, this ‘genomic grade index’
(GGI) was strongly associated with risk of recurrence among patients with grade 2
tumors.17,18 Similar to MammaPrint®, this assay is microarray based and requires freshly
prepared tissues and high-quality RNA.
Breast Cancer IndexSM (BCI)
The Breast Cancer IndexSM (BCI; BioTheranostics, San Diego, CA) prognostic assay
provides an assessment of the likelihood of distant recurrence in patients diagnosed with
ER-positive, node-negative breast cancer. In development and validation studies, BCI
stratified nearly 50% of tamoxifen-treated ER-positive, node-negative patients with breast
cancer into a low-risk group for 10-year distant recurrence.19,20 Unlike the other
commercialized tests, BCI has been developed from the combination of two indices: the
HOXB13:IL17BR two-gene ratio, which predicts distant recurrence in patients with ER-
positive disease treated with tamoxifen,21 and a proliferation-related five-gene molecular
grade index (MGI),19 which discriminates grade 1 from grade 3 disease (similar to the
MapQuant Dx™ assay). The BCI molecular assay is based on qRT-PCR using RNA from
FFPE tissues.
Intrinsic subtypes and PAM50 assay
Over the past 12 years, global gene-expression analyses have identified at least four breast
molecular subtypes known as the ‘intrinsic subtypes’ (luminal A, luminal B, HER2-enriched
and basal-like),22–25 which show significant differences in epidemiological risk factors,26
baseline prognoses,6,27,28 and responses to systemic therapies.28–32 Information provided by
the intrinsic subtypes, using an IHC-based approach, has also been adopted by the 2011 St
Gallen Consensus Conference (Table 2).4 The biological and clinical features of the intrinsic
subtypes of breast cancer have been extensively discussed in the literature and hence we will
focus on the most recent version of the intrinsic subtyping assay, known as the PAM50
assay.28,33 The training set for the PAM50 subtype predictor was composed of tumor
samples from 220 patients who had ER-positive or ER-negative tumors and HER2-positive
or HER2-negative tumors and from whom the prototypic samples of each molecular subtype
were identified using a list of 1,906 intrinsic genes; it also included 12 true normal breast
samples that constituted the normal breast-like centroid.28 A final minimized set of 50 genes
was derived from these prototypic samples, which comprises genes involved in proliferation,
ER and ER-regulated genes, HER2, and basal and myoepithelial characteristics.
The PAM50 assay provides a risk of relapse (ROR) score prognostic of relapse-free survival
for patients with node-negative tumors who did not receive adjuvant systemic therapy.28
The ability of the ROR score to predict prognosis (as a continuous variable or as a three-
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class variable) has been confirmed in an independent test set of 786 patients with ER-
positive disease treated only with adjuvant tamoxifen.33 In this cohort, the ROR together
with tumor size outperformed standard clinicopathological variables that included
expression of the proliferation marker Ki67, progesterone receptor (PR) and histological
grade.33 In addition, a ROR model that contained a proliferation component (derived using
11 of 50 PAM50 genes associated with cell-cycle function) improved the original model,
showing that the best model may contain variables for molecular subtype, tumor size and
proliferation status. Interestingly, this 11-gene proliferation signature has been found to have
more prognostic value than the expression of Ki67 assessed by IHC.33 The PAM50 assay is
compatible with FFPE-derived RNA and is currently being developed for clinical use on the
NanoString nCounter™ Analysis System (Nanostring technologies, Seattle, WA).34 It is
also offered using a qRT-PCR format from ARUP Laboratories (Salt Lake City, UT) as a
laboratory-developed test (that is, developed, evaluated, and validated within one particular
laboratory) waived by the CLIA (Clinical Laboratory Improvement Amendments).
The intrinsic molecular subtypes are correlated with standard pathological markers based on
gene-expression analysis.28,35–38 For example, most luminal tumors are ER-positive and/or
PR-positive, and most HER2-enriched and basal-like tumors are typically HER2-amplified
and triple-negative tumors, respectively.28,35–38 It should be noted that intrinsic subtyping
by gene expression compared with standard pathological biomarkers are not interchangeable
classifications,28,35,37 which demonstrates that intrinsic subtypes are not simple
combinations of ER, PR, and HER2.
Predicting early-stage outcomes
Prognostic signatures in breast cancer consist mainly of changes in proliferation and/or ER-
regulated genes.5,6,27 These two biological processes in breast cancer are critical for
distinguishing the relatively good prognosis of the luminal A subtype (which is
characterized by low proliferation and high expression of ER-regulated genes) from the
worse prognosis of the luminal B, HER2-enriched, and basal-like subtypes (which are
characterized by a higher proliferation status).22–25 Thus, the low-risk groups defined by
Oncotype DX®, MammaPrint®, MapQuant Dx™ and PAM50-ROR are essentially
composed of a subset of luminal A tumors.7,18 This observation explains why the prognostic
ability of these different gene expression-based assays is similar, as most of them are
differentiating luminal A from all other subtypes.6,27
Fan et al.27 evaluated 323 different gene signatures (also called modules), including research
versions of Oncotype DX®, MammaPrint®, MapQuant Dx™ and PAM50-ROR, on a
microarray-based cohort of 550 patients with node-negative breast cancer who did not
receive adjuvant systemic therapy. This exploratory study showed that it is only within ER-
positive, luminal disease that robust prognostic predictions can be made, but not within ER-
negative, or within HER2-positive disease.27 Other investigators have identified immune-
related signatures that might be able to predict survival within HER2-positive or triple-
negative tumors; however, the ‘good’ prognostic group still showed a relatively high
likelihood of relapse.39,40 Thus, from a clinical utility perspective, prognostic gene-
expression-based assays are only indicated for patients with ER-positive, node-negative
disease for whom it might be adequate to say that hormonal and local therapies are
sufficient, and that chemotherapy may not be necessary.
The clinical utility of Oncotype DX® versus standard parameters in ER-positive, node-
negative disease has been prospectively examined.41,42 In a relatively small multicenter
study, treatment recommendations were changed for 31% of the patients based upon
Oncotype DX® outcomes versus standard pathology-based risk assessments, with the
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largest change being the use of hormonal therapy only, with the omission of chemotherapy
in 22.5% of cases. Similar data have been reported from an independent study of 135
patients.42 Thus, although the costs of these gene-expression-based tests might be high
relative to the costs of ER, PR and HER2 testing, the additional reduction in adjuvant
chemotherapy administration is likely to result in an overall cost saving,43,44 as well as
reduced toxicity and quality-of-life improvements for patients.
The clinical utility of Oncotype DX® and the other gene-expression-based assays in ER-
positive, node-positive breast cancer remains investigational. Although Oncotype DX®,
MammaPrint® and PAM50-ROR are able to identify different predicted risk groups with
statistically distinct outcomes, for those with ER-positive, node-positive disease, the low-
risk groups do not show a sufficiently low rate of recurrence (that is fewer than 10% relapse
rates at 8–10 years) to consider excluding adjuvant chemotherapy based on prognosis
alone.7,15,33,45,46 However, when the subset of patients with one-to-three positive lymph
nodes are considered, the low-risk groups of Oncotype DX® and MammaPrint® have
shown outstanding outcomes with hormonal therapy alone (that is <10% relapse rate at 5–10
years), which is similar to the outcomes previously observed in similar groups with node-
negative disease.45–47
Two large prospective clinical trials are underway to further establish the clinical utility of
Oncotype DX® and MammaPrint®.9,16 In the fully accrued TAILORx trial, patients with
ER-positive, HER2-negative, node-negative disease with a RS of 10 or less were given
hormonal therapy alone, patients with a RS of 11–25 were randomly assigned to receive
adjuvant hormonal therapy with or without chemotherapy, and those patients with a RS >25
received hormonal therapy and chemotherapy (standard of care). The primary end point is to
determine if adjuvant chemotherapy plus hormonal therapy is better than hormonal therapy
alone in those with a RS between 11 and 25. In addition, this trial will confirm whether
patients with a low RS have an extremely low risk of recurrence that excludes the need for
chemotherapy based on prognosis alone. In the MINDACT trial assessing the
MammaPrint® assay in patients with ER-positive, node-negative disease in the adjuvant
treatment setting will be assessed by standard clinicopathological prognostic factors using
Adjuvant!Online and MammaPrint®. The primary objective of MINDACT is to confirm
that patients with a ‘low risk’ prognosis according to MammaPrint® and ‘high risk’
prognosis according to clinical features can be spared chemotherapy without affecting
survival outcomes. On the basis of the recent results of MammaPrint® in patients with
positive lymph nodes,47 the MINDACT trial has also been amended to include patients with
one-to-three positive lymph nodes.
Predicting treatment response
In the neoadjuvant setting, pathological complete response (pCR) in the breast has been used
to determine the systemic response to chemotherapy agents, although pCR is only achieved
in 20–30% of patients.48 Across the intrinsic subtypes, pCR rates to standard anthracycline-
based and taxane-based chemotherapy have been found to be approximately 7% for luminal
A, 17% for luminal B, 36% for HER2-enriched, and 43% for basal-like.48 Thus, the vast
majority of patients that achieve a pCR have non-luminal A tumors. This explains, in part,
why gene-expression signatures that largely discriminate luminal A from non-luminal A
tumors can also predict pCR.49–51
The benefit of neoadjuvant hormonal therapies is also an area of interest, and a non-genomic
prognostic index based on tumor size, nodal status, Ki67 levels and ER status after treatment
with neoadjuvant hormonal therapy (known as the preoperative endocrine prognostic index
[PEPI]52) has been developed. This index was developed in the P024 letrozole versus
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tamoxifen trial,53 and validated as predictive of relapse-free survival in an independent
study of 203 postmenopausal women in the IMPACT trial.52 Interestingly, in the
neoadjuvant aromatase inhibitor trial ACOSOG Z1031, luminal A tumors (defined using
PAM50) achieved significantly higher rates of PEPI score zero (good prognosis) than the
luminal B tumors,54 consistent with luminal A tumors being associated with superior
outcome when treated with hormonal therapy alone.
In the adjuvant setting, prediction of chemotherapy and/or hormonal therapy efficacy relies
on survival end points from clinical trials in which patients have been randomized to
different treatments. The best data are from retrospective studies in which Oncotype DX®
has been evaluated;45,55 in the NSABP-B20 trial,55 patients with ER-positive, node-negative
breast cancer were randomly assigned to receive tamoxifen or tamoxifen plus chemotherapy
(cyclophosphamide, methotrexate and 5-fluorouracil [CMF]). On the one hand, the low-RS
Oncotype DX® group did not derive a survival benefit from the addition of chemotherapy
and the relapse rates with or without chemotherapy were <5% at 12 years. On the other
hand, the high-RS Oncotype DX® group had a large benefit from chemotherapy with an
absolute decrease in 10-year distant recurrence of 27.6%. Less clear was the benefit of
chemotherapy in the intermediate RS group in NASBP-B20, hence the design of the
TAILORx trial, which randomized treatment to chemotherapy versus observation in this
group.
In the SWOG 8814 trial,45 the Oncotype DX® assay was applied to 219 patients with ER-
positive, node-positive disease randomly assigned to receive adjuvant fluorouracil,
doxorubicin and cyclophosphamide (FAC) followed by tamoxifen versus tamoxifen alone.
The benefit of FAC was only seen in the high-RS group. Importantly, further subanalysis
within the group with one-to-three positive nodes indicated that the relapse rates at 5 years
in the low-RS group was <10% regardless of the type of chemotherapy use. These results,
together with the TransATAC findings in patients with one-to-three positive nodes,46 has
led to the initiation of the RxPONDER clinical trial (NCT01272037) where around 4,000
patients with ER-positive breast cancer with one to three positive lymph nodes and a RS ≤25
will be randomized to hormonal therapy alone or chemotherapy followed by hormonal
therapy.
Reproducibility of breast biomarkers
The reproducibility of genomic biomarkers has drawn considerable attention, which
prompted us to investigate the issue of current biomarker reproducibility. Our review of the
literature suggests that standardized gene-expression-based assays such as Oncotype DX®
and MammaPrint® are more reproducible8,56,57 than current methodologies for ER, PR and
HER2 testing.58,59 Currently offered gene-expression-based assays are single platform or
single technology based (and sometimes even carried out within a single laboratory as is the
case for Oncotype DX®) and follow a single protocol. This high level of standardization
should be considered as a strength of these gene-expression-based assays as the existing
breast cancer biomarker field is plagued by nonstandardized tests that do not require, or
achieve, high levels of inter-laboratory concordance.
Since 2007, ASCO and the College of American Pathologists (CAP) have issued
recommendation guidelines for ER, PR and HER2 testing.58,59 These recommendations
summarized the various validated assays and provide a common scoring algorithm;
however, many standardization issues remain. Indeed, ASCO and CAP note that 20% of ER,
PR and HER2 measurements in the clinical setting are possibly inaccurate.58,59 This should
be taken seriously as the status of these biomarkers dictates therapeutic decision making. In
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fact, if a new genomic or proteomic assay was to be put forth today with a 20% discordance
rate, it likely would not be approved for clinical use.
In Table 3, we present a summary of the literature regarding reproducibility and
concordance for the current breast cancer biomarker tests, and we distinguish the
concordance between two identical protocols (inter-observer and inter-laboratory) and
between two different methods (inter-method). A commonly used measure of reproducibility
or concordance is the kappa (κ) statistic,60 which has an output range from −1 (total
discordance) to +1 (total concordance). The following three categories based on κ values are
used to define levels of concordance using concordance correlation coefficients: 0.40–0.60
(moderate concordance—defined here as level 3), 0.61–0.80 (substantial concordance—
level 2) and ≥0.81 (almost perfect agreement—level 1).61–63
When two observers, or laboratories, use identical protocols (inter-observer and inter-
laboratory studies), level 1 agreement is achieved for ER status defined by IHC and HER2
status defined by fluorescence in situ hybridization (FISH) when scored as a two-class
variable (variable of two elements: positive versus negative).64–76 For HER2 status, which is
usually scored as a three-class variable (0/1+, 2+ and 3+), level 1 agreement is observed in
most inter-observer studies,65,77–79 whereas level 2 agreement is observed in inter-
laboratory studies.71,73,76,79 The lower agreement achieved when the same HER2 IHC
protocol is carried out across two different laboratories might be due to pre-analytical
variables such as fixation times and/or in the critical area of subjectivity in IHC
interpretation, especially for the HER2 2+ cases.80,81 In the NCCTG-N9831 trial, Perez et
al.82 reported that 18.4% of 636 samples that were identified as HER2 3+ by the FDA-
approved HercepTest™ (Dako, Glostrup, Denmark) were not confirmed centrally by the
same assay; similar findings were noted in the NSABP-B-31 trial.83
Concordance between two different ER or PR testing methods—such as the concordance
between the ligand-binding biochemical assay and IHC64,69,84–86—or between two different
antibodies for ER,69,85,87 falls between level 2 and 3 (Table 3). It should be noted that
different antibodies are allowed in the USA for ER and PR testing, and thus, level 2–3 is the
current standard of reproducibility. For example, Rhodes et al.88 assessed histological
sections from breast cancers with low, medium and high levels of ER expression and sent
the samples to 200 laboratories for IHC staining where in-house techniques were used. The
results were then centrally evaluated. The inter-method staining results showed that 80% of
laboratories were able to demonstrate ER positivity in tumors with medium and high
expressing ER levels, whereas only 37% of laboratories scored adequately for the low-
expressing tumors. The low concordance within low ER-expressing tumors, together with
data suggesting that these tumors might still derive benefit from hormonal therapy,86,89 has
led the ASCO–CAP guidelines to recommend 1% positive cells or greater as the cutoff for
identifying a sample as ER-positive.59 Multi-class scoring of ER and PR into four or more
classes (using one antibody) by two pathologists shows level 3 concordance.64,67,90 Lastly,
level 2 and 3 concordances are typical for histological grade as estimated by two or more
pathologists;91–99 these levels of concordance are considered sufficient by some
investigators to recommend using tumor grade to help make therapeutic decisions.100
Concordance of HER2 status by different IHC based-antibodies,69,85,87 or IHC versus
FISH,77,101–104 also falls between level 2 and 3 (Table 3). In the NSABP B-31 trial, Paik et
al.83 found that 45% of 24 samples that had a community-based HER2 3+ score using a non-
HercepTest™ IHC test could not be confirmed by central HercepTest™. Interestingly,
concordance of HER2 FISH and HER2 gene expression, as determined by central
laboratories, falls within level 1 agreement,105,106 indicating that HER2 gene expression
might be a more reliable surrogate of HER2 amplification than HER2 protein by IHC.
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Overall, these data show that level 1 concordance can only be achieved in the clinical setting
when identical protocols are used (for example, the same IHC antibody); however, this is
not the current standard;58,59 instead, the current standards for ER, PR and HER2 testing
allow for different antibodies to be used, or allow different technologies to be used (FISH
versus IHC), and in these cases, level 2–3 concordance is observed and accepted for
therapeutic decision making. These results highlight the need to improve the reproducibility
of current diagnostic tests for patients with breast cancer, and we suggest that medical
practice should strive for level 1 concordance.
Reproducibility of gene-expression biomarkers
The Oncotype DX® and MammaPrint® assays have shown level 1 κ concordance values
and/or concordance correlation coefficients >0.90 when tested using the same starting
materials and when repeated on different days, with different reagent batches, and by
different technicians.,8,56,57 Clinical implementation of the 50-gene PAM50 subtype
predictor is currently underway, and thus, no published data exist to judge its
reproducibility; however, over the past decade, various research laboratory-based intrinsic
subtype predictors have been developed using the most advanced DNA microarrays and
statistical methods that are currently available. The identification of the intrinsic subtypes by
multiple investigators across the world, using many different expression technologies, has
been accomplished and has had an enormous impact, so that it is now commonplace to carry
out research-based intrinsic subtyping as a means of anchoring new findings to the literature.
The inter-observer concordance of different intrinsic subtype classifications using DNA
microarrays has been recently evaluated.62 Mackay et al.62 carried out 15 hierarchical
clustering analyses using five independent breast cancer microarray datasets and three
previously published intrinsic gene lists, and then estimated the agreement in identifying the
intrinsic subtypes (luminal A, luminal B, HER2-enriched, basal-like and normal-like) across
five observers. The results showed that the overall agreement was 0.64–0.70 (level 2), and
was >0.81 (level 1) for the basal-like and HER2-enriched subtypes, and substantial (κ = 0.6–
0.80, level 2) for the other subtypes (luminal A, luminal B and normal-like). Thus, the inter-
observer concordance of the intrinsic subtypes in the research setting by hierarchical
clustering analysis showed level 2 agreement (thus equivalent to current ER and HER2
testing), except for the basal-like and HER2-enriched subtypes that showed even better level
1 agreement.
The inter-method concordance of different molecular subtype classifications using DNA
microarrays was evaluated by Weigelt et al.63 who compared three different intrinsic
subtype prediction methods, each of which differed in three technological means (different
gene lists, different tumor training data sets, and different microarray platforms); these
analyses showed an overall κ value agreement of 0.24–0.74, and level 1 agreement for the
basal-like subtype, whereas the other subtypes had level 2–3. This experiment would be
similar to testing ER concordance using two different antibodies and the ligand-binding
assay, determining cut points using three different patient training sets, and then comparing
classification concordance results on yet other data sets. In addition, these substantial inter-
method concordance values were obtained despite the fact that the Weigelt et al.63 analyses
had several bioinformatic issues including a lack of microarray platform
normalization.107–109 In the research setting, when using two different normalization
procedures on the same data set before PAM50 intrinsic subtype classification, the κ
concordance value for the five subtypes will drop from level 1 to level 2 (A. Prat and C. M.
Perou, unpublished observations).
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Similar to ER IHC and HER2 FISH, level 1 concordance for any gene-expression-based
assay will only be achieved when using a single technology platform and a standardized
protocol. This protocol is the current standard for Oncotype DX® and MammaPrint®, and
the future protocol for intrinsic subtyping via the PAM50 assay. Overall, these results show
that intrinsic subtyping, as carried out in the research setting, is reproducible across
platforms and gene lists, and shows κ concordance values equivalent to current clinical
testing for histological grade, ER, PR and HER2 testing. The next challenge for gene-
expression- based assays will be to develop distributed assays that can maintain a similar
level of analytical reproducibility and clinical utility, as has been demonstrated by single
laboratories. Interestingly, a recent multisite reproducibility study of an FDA-approved
microarray-based gene-expression test for identifying the tissue site of origin for tumors of
unknown origins, known as Pathwork® (Pathwork Diagnostics, Redwood City, CA),
obtained κ concordance values >0.81 when testing 149 paired samples.110
The next decade
In the 12 years after the first publication of a gene-expression- based study on breast
tumors,25 it is clear that the information provided by gene-expression-based assays is useful
and deserves incorporation into clinical decision making. In fact, the term ‘molecular
portraits’ was coined based on the fact that in the vast majority of tumors, different pieces of
the same tumor, or primary tumor-metastasis pairs, are paired together when using gene-
expression data and a hierarchical clustering analysis.22–24,111 To further illustrate this point,
we re-analyzed 43 tumors with two or more distinct tumor aliquots or fragments (for
example, one primary tumor cut into two fragments or a tumor-metastasis pair assessed with
two RNA preps, and two microarrays) that were independently arrayed using data from
Harrell et al.,112 and found that 41 of 43 were paired together (Figure 1). If we call pairing a
successful classification (that is, inter-individual concordance), this 43 class classification
analysis yields a κ value of 0.95 (near perfect agreement). Thus, gene-expression analysis
not only accurately classified samples into common groups, but is also able to identify the
true individuality of each tumor, thus showing that each tumor is in a unique and
reproducible class by itself.
Conclusions
Current clinical recommendation for Oncotype DX® from ASCO–CAP and NCCN
guidelines and the 2011 St Gallen consensus report support the use of gene- expression-
based assays in the management of breast cancer. In the coming decade it is also likely that
further improvements in gene-expression-based assays will occur and make a clinical
impact, as will the discovery and implementation of new gene signatures. In addition, new
and exciting technologies will also make a clinical diagnostic impact, with the most
immediate possibilities being based on next-generation sequencing technologies,
proteomics, or in the isolation and characterization of special cell populations such as
circulating tumor cells. The first complete breast-cancer genomes have been published and
revealed a myriad of somatic mutations,113,114 some of which may be therapeutically
targetable. These are exciting times and we look forward to continued refinements of
existing assays and new discoveries in the decade to come, so that outcomes for patients
with breast cancer will continue to improve.
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• Gene-expression-based assays provide independent prognostic information
beyond standard clinical-pathological variables; however, tumor and nodal stage
remain important and must be taken into account in the final prognostic
assessment
• Gene-expression-based assays identify patients with ER-positive node-negative
disease at low risk of relapse after treatment with hormonal therapy and who
might be spared from chemotherapy
• Clinical use of gene-expression-based assays for the prediction of chemotherapy
benefit in node-positive disease, and in ER-negative disease, is currently
experimental
• Current methodologies for ER, PR and HER2 testing might benefit from
additional protocol standardizations, but may still be less reproducible than
standardized gene-expression-based assays
• Non-standardized research-based identification of the intrinsic subtypes shows
concordance values equivalent to current clinical testing for histological grade,
ER, PR and HER2
• For daily clinical use, we recommend the highest level of reproducibility/
concordance (Level 1), which will only be achieved for pathology and gene-
expression-based tests by using a single platform and standardized protocol
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Identification of tumor individuality using global gene-expression analyses. a | Supervised
hierarchical clustering of breast cancer data from Harrell et al.112 of 367 breast samples
using 1,900 intrinsic genes. Paired tumor samples are highlighted by the red lines in the
array tree, with 41 out of 43 possible pairs being paired. The two paired samples that did not
pair together are shown in green and light blue color. Note that one of each paired sample
was a primary tumor sample that was present within the normal-like cluster, which suggests
that both were highly contaminated with true normal breast tissue. b | A subset of the basal-
like array tree showing the different array names. Note that some tumors had more than two
samples, and in all cases, these were all grouped together. Abbreviations: INT, second
partner of an intrinsic pair (that is, two distinct pieces of the same primary tumor); LN,
lymph-node metastasis; Met, distant metastasis; Meta, metaplastic.
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Table 2
2011 St Gallen consensus recommendations of systemic treatment4
IHC Subtype Definition Type of adjuvant therapy
Luminal A HR+/HER2−/Ki67low Endocrine therapy alone*
Luminal B HR+/HER2−/Ki67high Endocrine therapy ± cytotoxic therapy
Luminal B HR+/HER2+ Cytotoxics + anti-HER2 + hormonal therapy
HER2-positive HR−/HER2+ Cytotoxics + anti-HER2 therapy
Triple-negative HR−/HER2− Cytotoxic therapy
*
A few patients require cytotoxics (such as high nodal status or other indicator of risk). Abbreviation: HR, hormone receptor.













Prat et al. Page 20
Table 3
Reproducibility data of currently used biomarkers in breast cancer
Level of agreement Type of test Identical protocols (inter-laboratory
and/or inter-observer)
Different protocols or technologies
(inter-method)
Level 1 (κ ≥0.81)
Almost perfect
agreement
Pathology test • ER IHC testing, same
antibody (+ vs −)64–70
• HER2 FISH testing (+ vs
−)71–76
• HER2 IHC testing, same
antibody (+ vs −)65,77–79
NA
Gene-expression-based test • Oncotype DX® and
MammaPrint®8,56,57
• Basal-like and HER2E
subtypes by supervised HC
using different (microarray-
based) intrinsic gene lists62
Basal-like by different gene list and
microarray platform intrinsic subtype
centroid predictors (microarray-
based)63,107–109
Level 2 (κ 0.60–0.80)
Substantial agreement
Pathology test • HER2 IHC testing, same
antibody (+ vs −)71,73,76,79
• Histological grade92,94,99
• PR IHC testing (+ vs −)65,66
• ER IHC, 3 or more groups64
• ER IHC by different
antibodies69,85,87
• ER by IHC vs LBA64,69,84–86
• HER2 IHC by different
antibodies104,115–117
• HER2 by IHC vs
FISH77,101–104
Gene-expression-based test • Overall intrinsic molecular
subtypes identied by
supervised HC using
different intrinsic gene lists
(microarray-based)62
• Luminal A/luminal B/
normal-like identied by
supervised HC using
different intrinsic gene lists
(microarray-based)62
Overall intrinsic molecular subtypes by
different gene list and microarray
platform intrinsic subtype centroid
predictors63,107–109
Level 3 (κ 0.40–0.59)
Moderate agreement
Pathology test Histological grade91–98
ER IHC with 4 or more groups64,67,90
PR IHC with 4 or more groups90
• PR by IHC vs LBA84
• PR IHC by different
antibodies68,87,118
• ER IHC by different
antibodies72,118
• HER2 by IHC/FISH vs
FISH72
Gene-expression-based test NA • Risk category groups*
comparing Oncotype DX®
vs MammaPrint® and
Oncotype DX® vs PAM50-
ROR
• Overall intrinsic molecular
subtypes by different gene
list and microarray platform
intrinsic subtype centroid
predictors63,107–109
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Level of agreement Type of test Identical protocols (inter-laboratory
and/or inter-observer)









All risk category groups have been calculated in the NKI295 dataset.15 For κ value calculation, low and intermediate groups of Oncotype DX®
have been combined into a low-risk group when compared with two risk groups from MammaPrint®. For intrinsic molecular subtyping, a higher
level of concordance is achieved when performing microarray platform to platform normalization, which was not performed by Weigelt et al.63
Abbreviations: ER, estrogen receptor; FISH, fluorescence in situ hybridization; HC, hierarchical clustering; HER2E, HER2-enriched; IHC,
immunohistochemistry; LBA, ligand-binding assay; NA, not applicable; PR, progesterone receptor.
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